World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Search
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Dedifferentiated liposarcoma (DDLPS)
An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
One step further in fighting rabies in Vietnam
A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages.
Angels Initiative in South Africa
Dr Stacey Rossouw explains how the Angels initiative is making a difference in South Africa and optimizing stroke care
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
It Takes 2
It Takes 2 people – a patient and a HCP, and 2 tests – a blood and a urine test–to help detect CKD. Early testing can drive earlier diagnosis and treatment.
Dog parasites: What you should know
From ticks, fleas, and mites to worms: there are many different parasite species that can harm your dog. Find out how to prevent and treat them here.
Microbial Expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins. Due to the variety of molecular formats that can be synthesised by microbes, microbial manufacturing is characterized by a broad width of production processes.
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Stroke Prevention in AF
Stroke Prevention in AF
Agile working as a mindset
How does an agile mindset foster innovation? Read about collaboration, user-centricity and rapid learning cycles
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Interstitial lung disease in rheumatoid arthritis (RA-ILD)
Interstitial lung disease (ILD) is the most common type of lung condition associated with the systemic autoimmune disease rheumatoid arthritis (RA).
Future Leaders in Veterinary Medicine and Research
Through the Boehringer Ingelheim Veterinary Scholars Program, we offer opportunities for students to gain research experience and explore new career paths.
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
world rabies day 2019
world rabies day 2019
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction